Selective Translation Regulator Inhibitors: Depriving cancer of what it needs

The Drug Discovery World Podcast

Content provided by Drug Discovery World and Drug Discovery World (DDW). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Drug Discovery World and Drug Discovery World (DDW) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

8M ago 17:51

MP3•Pagina episodului

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.

In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.

Dr Worland has significant experience as a scientist and C-suite level executive/entrepreneur, and today speaks about how Selective Translation Regulator Inhibitors (STRIs) are unique to other cancer treatments, the future of the industry as well as the significance of pharma collaboration in the development process.

You can find the Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

156 episoade

#Drugdevelopment #Drugdiscovery #Enablingtechnologies #Healthcare #Personalisedmedicine #Pharma #Biology #Informatics #Fitness #Drug Discovery World #Biopharma #Pharmacology #Science #Medicine #Business #Therapeutics #Drug Discovery World DDW #Screen